MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

Search

Grifols SA

Chiusa

SettoreFinanza

10.28 0.19

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.245

Massimo

10.345

Metriche Chiave

By Trading Economics

Entrata

17M

69M

Vendite

183M

2B

P/E

Media del settore

42

24.968

EPS

0.088

Margine di Profitto

3.491

Dipendenti

23,800

EBITDA

57M

482M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+16.62% upside

Dividendi

By Dow Jones

Utili prossimi

29 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.4B

6B

Apertura precedente

10.09

Chiusura precedente

10.28

Notizie sul Sentiment di mercato

By Acuity

35%

65%

132 / 538 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Grifols SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 apr 2025, 17:19 UTC

Acquisizioni, Fusioni, Takeovers

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 apr 2025, 13:02 UTC

Acquisizioni, Fusioni, Takeovers

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 apr 2025, 10:13 UTC

Acquisizioni, Fusioni, Takeovers

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 lug 2024, 10:40 UTC

Acquisizioni, Fusioni, Takeovers

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 lug 2024, 09:13 UTC

Acquisizioni, Fusioni, Takeovers

Grifols Faces Delisting Bid From Founding Family and Brookfield

15 apr 2025, 09:55 UTC

Discorsi di Mercato

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2 apr 2025, 09:27 UTC

Azioni calde

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Confronto tra pari

Modifica del prezzo

Grifols SA Previsione

Obiettivo di Prezzo

By TipRanks

16.62% in crescita

Previsioni per 12 mesi

Media 12 EUR  16.62%

Alto 13 EUR

Basso 11 EUR

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Grifols SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

1

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 8.566Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

132 / 538 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.